Antibacterial drugs are classified into β-lactams, macrolides, tetracyclines, aminoglycosides, sulfonamides, phenicols, quinolones, and miscellaneous antibacterial drugs. Quinolones is a major class of antibacterial drugs. Quinolones/fluoroquinolones are synthetic antibacterial drugs that exhibit a specific function of inhibiting the nucleic acid synthesis. Depending on their bactericidal properties, quinolones are effective against bacterial infections of the skin, the sinuses, the lungs, the stomach, and the urinary tract. With their property of inhibiting the nucleic acid synthesis, these drugs can interfere with the human DNA synthesis, as humans have the same basic nucleic acid constituents as those of bacteria. Quinolones exhibit rapid bactericidal activity, wherein they easily penetrate the bacterial cell membrane and reach the DNA where they bind to bacterial topoisomerases such as DNA gyrase, thereby inhibiting the bacterial nucleic acid synthesis.
There have been side-effects associated with the use of quinolones, due to which some of the drugs such as Tequin (gatifloxacin) manufactured by Bristol-Myers Squibb have been withdrawn from the market in a very short span after their launch (in 2006). According to the United States Food & Drug Administration (U.S. FDA), Tequin was discontinued due to adverse reactions in 2.7% of more than 5,000 treated patients. Some of the first-generation quinolones include nalidixic acid and cinoxacin. Also, nalidixic acid was among the first quinolone drugs that were utilized for treating urinary tract infections way back in 1962. Quinolones exhibit significant bactericidal activity and hence, they have been widely utilized in treating bacterial infections of the skin, the sinuses, the lungs, the stomach, and the urinary tract.
Key driver for the quinolones/fluoroquinolones market is the increasing prevalence of infectious diseases led by emergence of various mutant bacterial strains worldwide. Other drivers include increasing occurrence of multi-drug resistant forms of bacteria, which raises health care concerns and thereby, provides ample growth opportunities to drug manufacturers. Due to their numerous benefits over other antibacterial drugs, quinolones may replace other drug therapies to some extent. These beneficial characteristics include good oral absorption, easier tissue penetration, lower side-effects, easier dosage of once or twice a day, and a broad-spectrum activity against several pathogenic bacterial strains. However, patent expiries of leading antibacterial drugs of this class, narrow product pipeline, and availability of different generic drugs may restrain the quinolones market in the near future.
Some of the most widely used quinolones available for human use are norfloxacin (the first quinolone approved in 1986) and ciprofloxacin (approved in 1987). Other important quinolones include ofloxacin (1990), enoxacin (1991), lomefloxacin (1992), levofloxacin (1996), trovafloxacin (1997), gatifloxacin (1999), and moxifloxacin (1999). The leading branded drugs available in the global quinolones market are Avelox/Avalox (moxifloxacin), Cipro/Ciprobay (ciprofloxacin), Zymaxid (gatifloxacin), Levaquin, and Tavanic (levofloxacin).
The global quinolones market can be segmented based on type, distribution channel, and region. Based on type, the market can be divided into norfloxacin, ofloxacin, ciprofloxacin, levofloxacin, gemifloxacin, grepafloxacin, gatifloxacin, sparfloxacin, enoxacin, and moxifloxacin. Based on distribution channel, the global quinolones market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. Geographically, the global quinolones market can be segmented into five key regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America and Asia Pacific hold a leading share of the global quinolones market. Increasing prevalence of infectious diseases in developing countries offers immense growth opportunities to the quinolones market in these countries.
Key players operating in the global quinolones market are Bayer AG, Sanofi, Johnson & Johnson, Merck & Co, Inc., LG Life Sciences, Allergan, Inc., and Novartis AG.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.